Aduhelm: Case Study on Paying for Health by Paul Seegert
Insurance Thought Leadership - Nov 07, 2021
In July, I wrote an article that criticized the newly authorized Alzheimer’s drug Aduhelm. Six months later, the market response is heartening and, in my opinion, a case study in what it will take to fix the way that we pay for healthcare in America. A review of the problem The FDA approved the fi...
Recommended Articles
Posted: Apr 14, 2026
A Hopeful Conversation on Climate Risk PaulCarroll Tue, 04/14/2026 - 12:03 My favor...
Posted: Apr 10, 2026
Un-Connected Dots: Why We Don’t Prevent Fraud Cyber ITL Editorial Team F...
Posted: Apr 10, 2026
Unconnected Dots: Why We Don’t Prevent Fraud Cyber ITL Editorial Team Fr...